AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
2010; Springer Science+Business Media; Volume: 215; Issue: 1 Linguagem: Inglês
10.1007/s00213-010-2124-0
ISSN1432-2072
AutoresMark D. Black, Rachel J. Stevens, Nancy Rogacki, Robert E. Featherstone, Yaw Senyah, Odessa Z Giardino, Beth Borowsky, Jeanne Stemmelin, Caroline Cohen, Philippe Pichat, Michal Arad, Segev Barak, Amaya De Levie, Ina Weiner, Guy Griebel, Geoffrey B. Varty,
Tópico(s)Neurotransmitter Receptor Influence on Behavior
Referência(s)